Intellia Therapeutics Inc. stocks have been trading up by 13.94 percent after promising CRISPR gene-editing trial progress boosted optimism.
Click Here for a Millionaire's POV on Trading NTLA
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Q1 2026 revenue of $15.0M topped the $13.8M consensus, while the net loss narrowed to $0.81 per share versus $1.10 a year ago and beat expectations.
- Strong Phase 3 data for lonvoguran ziclumeran in hereditary angioedema drove a rolling BLA, with a potential U.S. launch targeted in 1H 2027.
- FDA‑cleared Phase 3 trials for nexiguran ziclumeran in ATTR are back on track, and an April equity raise pushed Intellia’s cash runway into at least 2028.
- ARK Investment, led by Cathie Wood, bought 214,000 shares in one trading session, flagging renewed institutional interest in NTLA.
- Canaccord and H.C. Wainwright trimmed price targets but kept Buy ratings, while Bernstein raised its target amid a more constructive biotech backdrop.
Live Update At 14:03:01 EDT: On Thursday, June 04, 2026 Intellia Therapeutics Inc. stock [NASDAQ: NTLA] is trending up by 13.94%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
NTLA has been acting like a classic biotech rebound chart. Over the last couple of weeks, Intellia Therapeutics shares have climbed from the $11–$12 range to a close of $14.835 on 2026/06/04, a strong near‑term uptrend. The daily candles show a series of higher lows from 2026/05/20 onward, telling traders that dip buyers are stepping in consistently.
Intraday, NTLA traded from a pre‑market base around $13.00 to a high near $15.49 before cooling slightly into the close. That intraday ramp, with tight five‑minute candles holding above $14.70 for much of the afternoon, signals firm demand and suggests shorts are on the back foot for now.
More Breaking News
- LAES Stock Steadies As SEALSQ Builds Quantum Powerhouse
- SMR Stock Slips As Wall Street Slashes Price Targets
- ACHR Stock Slips As Loss Guidance And Insider Selling Weigh
- YMAT Stock Soars As Texas Battery Loan Gets Green Light
Fundamentally, Intellia posted Q1 2026 revenue of $15.0M, beating the $13.8M consensus. The net loss improved to $0.81 per share from $1.10 a year earlier and also beat expectations. This is still a heavy‑loss, high‑burn biotech, but the company is outpacing Wall Street’s models. With $375.986M in cash and short‑term investments and a current ratio around 6, NTLA has meaningful runway to keep funding late‑stage trials without urgent financing pressure, which matters for traders worried about surprise offerings.
Why Traders Are Watching NTLA Now
Intellia Therapeutics is shifting from early science story to late‑stage execution, and that is when biotech charts can move the most. The star of the NTLA story is lonvoguran ziclumeran, or lonvo‑z, its in vivo CRISPR therapy for hereditary angioedema. The company reported strongly positive Phase 3 data and has already kicked off a rolling biologics license application, aiming for a U.S. launch in the first half of 2027. For traders, that means a clear regulatory path and a real commercial timeline, not just blue‑sky talk.
At the same time, NTLA resumed FDA‑cleared Phase 3 trials for nexiguran ziclumeran in ATTR amyloidosis. That gives Intellia a second late‑stage shot on goal. Markets usually pay up when a platform company shows more than one serious program moving toward approval.
The April equity raise was dilutive, and you see that in analyst moves. H.C. Wainwright cut its price target to $25 from $30, and Canaccord dropped its target to $49 from $58. But both stuck with Buy ratings, framing the raise as the cost of extending the cash runway into at least 2028. Bernstein actually went the other way, lifting its target to $17 and pointing to a friendlier biotech backdrop with active M&A and supportive FDA leadership.
Layer on ARK Investment’s purchase of 214,000 shares in a single session, and you have a name that big funds are willing to lean into again. Upcoming catalysts add fuel: Intellia will present late‑breaking Phase 3 data from the HAELO trial of lonvo‑z at the EAACI 2026 congress and speak at multiple healthcare conferences. Those events are classic trading setups where new slides or comments can trigger fast moves in NTLA, up or down.
Conclusion
For active traders, NTLA now sits at the crossroads of strong science, visible catalysts, and cleaner financing risk. The stock has already pushed from the low teens to the mid‑teens, riding Q1 beats and major Phase 3 wins. Intellia Therapeutics remains unprofitable, with steep negative margins and a high price‑to‑sales multiple, so this is still a story dominated by trial data and regulatory headlines, not earnings power.
What has changed is the quality of those headlines. Lonvo‑z has positive Phase 3 data and a rolling BLA underway, nex‑z Phase 3 work has restarted, and the balance sheet looks funded into at least 2028 after the equity raise. Analyst reactions around NTLA reflect that mix: some trimmed targets on dilution, others nudged targets higher as the biotech tape and regulatory climate improve. ARK’s recent buy adds a momentum angle that short‑term traders watch closely. As Tim Bohen, lead trainer with StocksToTrade says, “I focus on momentum that’s visible right now. Speculation on future moves is outside my playbook.” For many momentum‑focused traders watching NTLA, that mindset means zeroing in on the current catalysts and price action rather than trying to forecast far‑off scenarios.
As Tim Sykes likes to say, “The market rewards preparation, not prediction.” For NTLA, preparation means knowing the key dates — the EAACI 2026 data presentation, upcoming conference talks, and future regulatory updates — and watching how price, volume, and news flow line up. This article is for educational and research purposes only, but the message for traders is clear: Intellia Therapeutics has become a catalyst‑driven biotech where both breakouts and sharp pullbacks will favor those who study the pattern, respect risk, and cut losses fast.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.